2250024-74-7
2250024-74-7 structure
- Name: DDO-2093
- Chemical Name: DDO-2093
- CAS Number: 2250024-74-7
- Molecular Formula: C29H37ClFN9O3
- Molecular Weight: 614.11
- Catalog: Signaling Pathways Epigenetics Histone Methyltransferase
- Create Date: 2021-09-15 18:00:07
- Modify Date: 2024-01-13 19:20:23
-
DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex[1].
| Name | DDO-2093 |
|---|
| Description | DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex[1]. |
|---|---|
| Related Catalog | |
| In Vitro | MV4-11(harboring MLL-AF4 fusion protein) and MOLM-13 (harboring MLL-AF9 fusion protein)[1]. DDO-2093 (5 μM; pretreated 7 days) inhibits MLL-fusion protein dependent genes expression (HOXA9 and Meis1)[1]. Western Blot Analysis[1] Cell Line: MV4-11 cells Concentration: 1, 2.5, 5, and 10 μM Incubation Time: Pretreated 7 days Result: Dose-dependently reduced the mono-, di-, and trimethylation of H3K4. |
| In Vivo | DDO-2093 (20 mg/kg-80 mg/kg; i.p.; every other day for 21 days) significantly suppresses the tumor size and weight in a dose-dependent manner[1]. Animal Model: Female nude mice (MV4-11 human leukemia cancer xenografts)[1] Dosage: 20 mg/kg, 40 mg/kg and 80 mg/kg Administration: I.p.; every other day for 21 days Result: The tumor volume growth inhibition (GI) values were calculated to be 13.7%, 37.6% and 63.9% with doses of 20 mg/kg, 40 mg/kg and 80 mg/kg, respectively. |
| References |
| Molecular Formula | C29H37ClFN9O3 |
|---|---|
| Molecular Weight | 614.11 |